glp 1 agonists approved for weight loss The New Management Meds Comparing GLP-type therapies for weight

P =0.532) and women (IRR, 0.95

45,160 In summary, most of the studied drugs did not show clinically significant DDIs related to delayed gastric emptying caused by GLP-1 RAs or a dual GLP-1/GIP RA administration

Nathaniel Chin, medical director of the Wisconsin Alzheimers Disease Research Center, the results were not surprising

Glucagon-like peptide-1 receptor agonists as an effective therapeutic agent for diabetes mellitus and obesity in patients with schizophrenia under treatment with second-generation antipsychotics

A comparison of Parkinsons disease patients, disease controls and healthy individuals

doi: 10.2337/ds20-0033